Earnings ·
Arcutis raises full-year sales guidance to $545M as Q3 revenue grows 45% to $143.9 million
ARQTArcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics reported third-quarter net product revenues of $143.9 million, a 45% increase from the prior year and an 11% rise sequentially, driven by strong demand for its ZORYVE portfolio. The company raised its full-year 2026 net product sales guidance to $535 million–$545 million from the previous range of $525 million–$540 million. Net income was $8.8 million, or $0.07 per share basic and $0.06 diluted, compared to $7.4 million in the same period last year. Operating cash flow remained positive at $18.9 million for the quarter. Arcutis is a commercial-stage biopharmaceutical company focused on developing innovative treatments for immune-mediated dermatological diseases.